Literature DB >> 3181667

Antithrombin III concentrate in the treatment of fulminant hepatic failure.

K Fujiwara1, K Okita, K Akamatsu, H Abe, Y Tameda, T Sakai, N Inoue, K Kanai, N Aoki, H Oka.   

Abstract

Twenty-six patients with fulminant hepatic failure were treated with daily infusions of antithrombin III concentrate until recovery of consciousness or death. Seven patients were alive (group A), 7 survived 17 to 47 days after treatment (group B), and 12 died within 9 days (group C). Decreased plasma antithrombin III levels increased on the day after treatment, irrespective of the pretreatment levels in all patients. Continuous or temporary normalization was seen in all patients in groups A and B, but in only 5 in group C patients whose bleeding was extensive (p less than 0.05). An abrupt drop in peripheral platelet counts occurred when plasma antithrombin III levels were below normal. General bleeding accompanied this drop. These results suggest that maintained normal plasma antithrombin III levels are beneficial for prolonged survival time in fulminant hepatic failure, probably through controlling intravascular coagulation, and that antithrombin III infusion may be useful for such treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3181667     DOI: 10.1007/bf02779211

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  14 in total

Review 1.  Intravascular coagulation in liver disease.

Authors:  M Verstraete; J Vermylen; D Collen
Journal:  Annu Rev Med       Date:  1974       Impact factor: 13.739

2.  Anticoagulant action of heparin.

Authors:  P S Damus; M Hicks; R D Rosenberg
Journal:  Nature       Date:  1973-12-07       Impact factor: 49.962

3.  The purification and mechanism of action of human antithrombin-heparin cofactor.

Authors:  R D Rosenberg; P S Damus
Journal:  J Biol Chem       Date:  1973-09-25       Impact factor: 5.157

4.  Acute hepatic failure--in special relation to treatment.

Authors:  Y Takahashi
Journal:  Jpn J Med       Date:  1983-04

5.  Disseminated intravascular coagulation in hepatic failure treated with antithrombin III.

Authors:  B Laursen; J Z Mortensen; L Frost; K B Hansen
Journal:  Thromb Res       Date:  1981 Jun 1-25       Impact factor: 3.944

6.  A controlled trial of heparin therapy in the coagulation defect of paracetamol-induced hepatic necrosis.

Authors:  B G Gazzard; R Clark; V Borirakchanyavat; R Williams
Journal:  Gut       Date:  1974-02       Impact factor: 23.059

7.  Significance of intravascular coagulation and fibrinolysis in acute hepatic failure.

Authors:  P Hillenbrand; S P Parbhoo; A Jedrychowski; S Sherlock
Journal:  Gut       Date:  1974-02       Impact factor: 23.059

8.  Treatment of DIC with antithrombin III concentrates.

Authors:  Y Sakata; N Yoshida; M Matsuda; N Aoki
Journal:  Bibl Haematol       Date:  1983

9.  Intravascular coagulation in acute liver failure in rats and its treatment with antithrombin III.

Authors:  K Fujiwara; I Ogata; Y Ohta; K Hirata; Y Oka; S Yamada; Y Sato; N Masaki; H Oka
Journal:  Gut       Date:  1988-08       Impact factor: 23.059

10.  Early and intensive therapy of intravascular coagulation in acute liver failure.

Authors:  M O Rake; P T Flute; K B Shilkin; M L Lewis; J Winch; R Williams
Journal:  Lancet       Date:  1971-12-04       Impact factor: 79.321

View more
  2 in total

1.  Use of prostaglandin I2 analog in treatment of massive hepatic necrosis associated with endothelial cell injury and diffuse sinusoidal fibrin deposition.

Authors:  K Fujiwara; S Mochida; A Ohno; M Arai; A Matsui; N Masaki; K Hirata; T Tomiya; M Yamaoka; S Nagoshi
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

2.  Antithrombin III injection via the portal vein suppresses liver damage.

Authors:  Masayuki Miyazaki; Masaki Kato; Masatake Tanaka; Kosuke Tanaka; Shinichiro Takao; Motoyuki Kohjima; Tetsuhide Ito; Munechika Enjoji; Makoto Nakamuta; Kazuhiro Kotoh; Ryoichi Takayanagi
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.